VLP Therapeutics, Inc., a Gaithersburg, Md.-based biotech company, raised US$16m in Series A funding.
Backers included MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ Fund in USA.
The company intends to use the funds for research and development of a cancer treatment vaccine, moving into clinical trials at the earliest date possible.
Co-founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, VLP Therapeutics is a biotech company currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, and novel coronavirus disease (COVID-19) using its proprietary platform technologies.
FinSMEs
22/03/2021